RxDoctor Payments Data

Mauna Pandya, MD

Hematology & Oncology · Oak Lawn, ILNPI 1356439178

Payments from drug & device makers

$17,556in general payments, 2019–2025

Across 834 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • AstraZeneca$1K
  • Merck$1K
  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$882
  • Bristol Myers Squibb$680
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$17,25698%
  • Education$3002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis78$1,239
AstraZeneca(2 entities)51$1,126
Merck56$1,123
Johnson & Johnson(2 entities)48$1,094
E.r. Squibb & Sons, L.L.C.58$882
Bristol Myers Squibb23$680
Pfizer39$674
Gilead(2 entities)30$603
Lilly USA, LLC23$564
Genentech USA, Inc.28$563
Eisai Inc.25$505
Amgen19$417
Takeda Pharmaceuticals U.S.A., Inc.14$412
Daiichi Sankyo Inc.16$386
GSK16$372
Astellas Pharma US Inc15$353
AbbVie16$336
Ipsen Biopharmaceuticals, Inc9$333
Sanofi15$297
Regeneron Healthcare Solutions, Inc.13$296
Incyte Corporation15$258
Seagen Inc.9$247
GE HealthCare9$222
Beigene USA, Inc.10$206
Jazz Pharmaceuticals Inc.8$190
Octapharma USA, Inc.1$177
Dova Pharmaceuticals13$177
Global Blood Therapeutics, Inc.8$158
Exelixis Inc.7$149
Agios Pharmaceuticals, Inc.7$148
Bayer8$143
Tersera Therapeutics LLC4$139
Pharmacyclics LLC, An Abbvie Company6$129
EMD Serono, Inc.6$129
Pharmacosmos Therapeutics Inc.6$124
Puma Biotechnology, Inc.6$116
Coherus Oncology, Inc.6$116
Deciphera Pharmaceuticals Inc.5$109
Morphosys, US Inc.5$107
Myriad Genetic Laboratories, Inc.4$100
G1 Therapeutics, Inc.5$99
Boehringer Ingelheim4$96
Karyopharm Therapeutics Inc.4$90
Novo Nordisk4$88
Mirati Therapeutics, Inc.4$82
Servier Pharmaceuticals LLC4$75
Foundation Medicine, Inc.3$74
Fresenius Kabi USA, LLC3$71
Geron Corporation2$68
Tempus AI, Inc3$67
Rigel Pharmaceuticals, Inc.3$65
Stemline Therapeutics Inc.3$60
Pharmaessentia USA Corporation2$60
Genmab U.S., Inc.2$58
ADC Therapeutics America, Inc.3$54
Clovis Oncology, Inc.3$53
Sobi, Inc2$52
Blueprint Medicines Corporation2$52
Taiho Oncology, Inc.3$51
AVEO Pharmaceuticals, Inc.2$48

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,556 in reported general payments places this provider in the 55th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$1,666,648
Medicare patients
640
Services billed
72,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib24$390,147
RevlimidLenalidomide22$375,828
ImbruvicaIbrutinib20$307,986
CabometyxCabozantinib S-Malate12$305,145
TagrissoOsimertinib Mesylate18$302,247
InlytaAxitinib12$157,298
EliquisApixaban91$85,540
XareltoRivaroxaban32$44,836
VenclextaVenetoclax11$11,710
Exemestane35$9,400
Anastrozole360$7,924
Enoxaparin Sodium17$4,984
Letrozole88$1,600
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen43$1,467
Fentanyl15$1,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Inlyta, Eliquis$674$632,985127 claims
Bristol Myers SquibbRevlimid$680$375,82822 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$129$307,98620 claims
Exelixis Inc.Cabometyx$149$305,14512 claims
AstraZenecaTagrisso$1,126$302,24718 claims
Johnson & JohnsonXarelto$1,094$44,83632 claims
AbbVieVenclexta$336$11,71011 claims
Lilly USA, LLCOlanzapine$564$13318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Oak Lawn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →